|
May11
|
The last 14 months of blogging here at Pharmagazette had been rewarding in more ways than one and I want to take this opportunity to thank the whole Know More Media team for believing in me. However, some things must end and after this post I will no longer be blogging for Pharmagazette. (I will still be blogging about health and science though, but outside the Know More Media network of business blogs.) While blogging about pharmaceutical business taught me huge stuff than I could ever learn somewhere else, it is something that I cannot do anymore. Thank you so much for frequenting this blog. I hope you still find time to visit when Know More Media finds a new resident blogger. And as for me, I will still be present in the blogosphere...so I hope you find me there some time soon. So long and best of luck and regards to Know More Media and its team of excellent professionals and wonderful people.
|
|
May10
|
Check out the following great posts from the blogosphere that I think would interest pharma business readers as well: Centrally Active ACE inhibitors May Help Reduce Risk of Cognitive Decline in Older Adults Twinject, Now With Enhanced Features Diabetes Drug...
Continue Reading
|
|
|
Manufactured by Schwarz Bioscience of Research Triangle Park, N.C. - Neupro® (rotigotine transdermal system), a skin patch designed to treat symptoms of early Parkinson's disease – has been approved by the USFDA. Neupro - the first transdermal patch approved for...
Continue Reading
|
|
May 8
|
Lupin Pharmaceuticals, Inc. has been granted final approval by the USFDA for its Abbreviated New Drug Application for Cefdinir for Oral Suspension, 250 mg/5mL. Lupin was the first company to receive FDA final approval for the capsule form on (May...
Continue Reading
|
|
|
Hugely favoring the pharmaceutical industry, the U.S. Senate killed the drive that would have allowed consumers to buy prescription drugs from abroad that is a lot cheaper than domestic prices. Prices of branded prescription drugs in the United States are...
Continue Reading
|
|
|
Bayer HealthCare Pharmaceuticals Inc. and Intendis Inc. will co-promote YAZ® (drospirenone/ethinyl estradiol) as a treatment for moderate acne in women who desire an oral contraceptive for birth control. The said agreement took effect May 1, 2007 as part of an...
Continue Reading
|
|
|
The USFDA has awarded a Fast Track Designation to Cell Therapeutics, Inc. (CTI) (Nasdaq: CTICD)’s pixantrone for relapsed indolent non-Hodgkin's lymphoma (NHL). Pixantrone is a novel anthracenedione, being investigated by CTI for the potential treatment of relapsed or refractory indolent...
Continue Reading
|
|
|
Preliminary data from IR BioSciences Holdings, Inc. (OTC: IRBO)’s influenza vaccine adjuvant study being performed in conjunction with GenPhar Inc. revealed that its compound – Homspera - elevates host immune responsiveness above that induced by vaccine alone system.The said data...
Continue Reading
|
|
May 7
|
Abbott (NYSE: ABT) has simultaneously submitted regulatory applications for its drug product HUMIRA® (adalimumab): a supplemental Biologics License Application (sBLA) with the USFDA seeking approval to market HUMIRA® (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the U.S....
Continue Reading
|
|
May 6
|
Abbott’s investigational treatment, ABT-874, has been found significantly effective in reducing the symptoms of psoriasis in majority of patients treated. Such were the findings from the new Phase II clinical data recently reported by Abbott (NYSE: ABT). At 12 weeks,...
Continue Reading
|
|
May 5
|
The USFDA has approved a new indication for FRAGMIN® (dalteparin sodium injection): extended treatment of symptomatic venous thromboembolism (VTE) [proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE)] to reduce the recurrence of VTE in cancer patients. In the United...
Continue Reading
|
|
|
The USFDA has awarded a three-year grant of $1,050,000 to Expression Genetics, Inc. in order to assist in the clinical development of EGEN-001, the company's lead oncology product. In 2005, EGEN-001 has been given Orphan Drug Status by the USFDA...
Continue Reading
|
|
May 4
|
Victory Pharma, Inc. (Victory) has recently completed the acquisition of the exclusive US marketing rights to its leading marketed pain product, Naprelan®, wherein Victory paid total consideration of $8.75 million to Hi-Tech Pharmacal Co., Inc. and Stat-Trade, Inc. Naprelan®, which...
Continue Reading
|
|
|
The leading provider of solutions for the exploration, interpretation, and analysis of life science information - Ingenuity Systems - has entered into an agreement with Wyeth for the extension and expansion of its licensing agreement for access to IPA software....
Continue Reading
|
|
|
Immediate initiation of Betaseron® (interferon beta-1b) treatment in patients with a first event suggestive of multiple sclerosis (MS) can significantly reduce the risk of permanent neurological impairment as measured by the Expanded Disability Status Scale (EDSS) by 40 % over...
Continue Reading
|
|
May 3
|
GlaxoSmithKline (NYSE: GSK)’s investigational once daily extended release formulation of Lamictal® (lamotrigine) - Lamictal® XR™ - has been found effective as add-on treatment in patients with partial epilepsy with and without secondary generalization. Currently, Lamictal® XR™ is being developed for...
Continue Reading
|
|
|
Check out these interesting blog entries, even pharmaceutical business blog readers will find them as informative as I did: Green Tea Compound May Treat Rheumatoid Arthritis Possible Obesity Pill Could be Link to Health New Prefilled Disposable Insulin Pen for...
Continue Reading
|
|
May 2
|
Duramed Pharmaceuticals, Inc. has recently announced the two new USFDA approvals given to ENJUVIA™ (synthetic conjugated estrogens, B) product: supplemental New Drug Application (sNDA) for 0.9 mg tablet strength, which will be added to the Company's existing ENJUVIA product line...
Continue Reading
|
|
|
The USFDA has approved CSL Behring’s factor replacement therapy for the treatment of hemophilia A and von Willebrand disease (VWD) - Humate-P® (Antihemophilic Factor/von Willebrand Factor Complex [Human]) – for the prevention of excessive bleeding during and after surgery in...
Continue Reading
|
|
|
You’ve probably noticed that my last post was dated April 27. That’s because I took my real vacation in a long time, with 4-year old my son and two oldest girl friends. First we went to the nearest nicest beach...
Continue Reading
|
